Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.

Moderna is a contrarian play for 2025, despite a rough 2024 as one of the worst-performing Nasdaq-100 stocks. Click here to ...

Less than a year after China identified the virus, health authorities in the U.S. and Britain cleared vaccines made by Pfizer ...

We recently published a list of 10 Firms End 2024 Stronger With Impressive Gains. In this article, we are going to take a ...

Moderna Inc (MRNA) stock saw a modest uptick, ending the day at $41.58 which represents a slight increase of $2.20 or 5.59% from the prior close of $39.38. The stock opened at $39.71 and touched a low ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

According to Benzinga Pro, Moderna's peer group average for short interest as a percentage of float is 4.49%, which means the ...

Shares of Moderna Inc. MRNA shed 1.87% to $39.38 Monday, on what proved to be an all-around grim trading session for the ...

Super Micro stock declines, Nvidia trades lower, and MicroStrategy shares extend losses after a sharp drop in the previous ...

A 13-year-old girl in Canada became so sick with H5N1, or bird flu, in late 2024 that she had to be put on a ventilator.

Moderna Inc (MRNA) stock saw a decline, ending the day at $40.13 which represents a decrease of $-0.30 or -0.74% from the prior close of $40.43. The stock opened at $40.35 and touched a low of $39.79 ...